Page History

Jeffrey Brown, TriNetX

Jeffrey Brown, PhD, Chief Scientific Officer at TriNetX and part-time lecturer part-time at Harvard Medical School (HMS), is an internationally recognised expert in using real-world data to support the evidentiary needs of regulatory agencies and medical product sponsors. He is also an expert in assessing data quality of real-world data resources. Dr Brown focuses on the value of collaborative research with an emphasis on federated networks. He has expertise in assessing the fitness-for-use of real-world data and matching questions to methods to data to generate robust evidence. He has nearly 20 years of experience facilitating large-scale, multi-institutional observational research through using distributed health data networks to support a learning health system and using electronic health data to support decision-making.

In his previous role as Associate Professor at Harvard Medical School, Dr Brown served as the Lead Data Scientist for the FDA Sentinel Operations Center and as a member of the Sentinel Operations Center Executive Committee. He has also been Principal Investigator of the analytic coordinating centre for the Innovation in Medical Evidence Development and Surveillance (IMEDS) programme and the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC). While at Harvard he also served as PI of several industry-sponsored multi-site pharmacoepidemiologic studies to support FDA and EMA regulatory requirements. Dr Brown holds a master’s degree in economics from Tufts University and a PhD in Social Policy from Brandeis University.

Image Added

Michèle Arnoe, IQVIA

During her career Michèle has followed all the stages of the drug development life cycle, from pre-clinical research to clinical development and commercialization. She initially worked for the French company Cegedim (technology and services in digital healthcare ecosystem) to launch their international expansion.

In 1999, Michele joined the global clinical organization Parexel where she became Vice President for Business Management and Strategy for the European Peri Approval division. She was responsible for both the sales and project management teams. The organization she built ensured a strong alignment between sales, project design, project management and client objectives. She also worked for Cerep S.A., leader in pre-clinical pharmacology and ADME-Tox services, where she was Global Head of Business Development for 6 years. Michèle then joined ScreenCell (a company designing medical devices in support of oncology diagnostics) in 2011 as VP Marketing & Business Development.

She came back to Cegedim in 2013 as General Manager for France Cegedim Strategic Data and VP Medical Research, then joined again the CRM (Customer Relationship Management) BU managing the Global account managers team focusing on Large Pharma. Following Cegedim’s acquisition by IMSHealth then the Quintiles IMS merger, Michèle was Head of Innovation in France then was appointed Head of Global Real World Data Assets with responsibilities focusing on RWD data visibility across geographies and functions including access, transformation, compliant usage thus aiming at leveraging secondary data when appropriate throughout the drug lifecycle.